Ozbek Nilgün, Birinci Asuman, Karaoglanoglu Ozden, Coban Ahmet Yilmaz, Okumus Baris, Cakir Saban, Durupinar Belma
Department of Radiation Oncology, School of Medicine, Ondokuz Mayis University, Samsun, Turkey.
Ann Saudi Med. 2004 Mar-Apr;24(2):106-11. doi: 10.5144/0256-4947.2004.106.
The concept of genetic factors playing a role in the pathogenesis of lung cancer has gained increased attention. The present study was undertaken to examine the question of HLA association with lung cancer and to investigate the effects of HLA on survival time.
The distribution of HLA class I (A, B, C) antigens and class II (DR, DQ) alleles were studied in 81 unrelated Turkish patients with lung cancer. The HLA status of patients was compared with that of a control group consisting of 117 ethnically matched healthy donors. HLA class I antigens were studied by Terasaki's microlymphocytotoxicity test and HLA class II alleles were studied by polymerase chain reaction with the sequence specific primer (PCR-SSP) low resolution method.
Only the frequencies of HLA-B51 and -DRB1x15 were lower in the lung cancer group compared with the healthy control patients. In a univariate analysis, age (P=0.03), Karnofsky Performance Status (P=0.0001), stage (P=0.01), HLAA24(9) (P=0.008), HLA B53 (P=0.0006), HLA B63(15) (P=0.01), HLA B64(14) (P=0.01), HLA B65(14) (P=0.01) and HLA CW5 (P=0.01) were significant prognostic factors. In a multivariate analysis, Karnofsky Performance Status (P=0.001), stage (P=0.02), HLA B53 (P=0.03) and HLA B64(14) (P=0.03) were independent prognostic variables.
This study demonstrates different HLA types among patients with lung cancer and healthy control subjects. Our results suggest that HLA antigens might affect the prognosis in lung cancer. Further investigations are warranted to delineate any possible role of the HLA system in the pathogenesis and prognosis of lung cancer.
遗传因素在肺癌发病机制中起作用的概念已受到越来越多的关注。本研究旨在探讨HLA与肺癌的关联问题，并研究HLA对生存时间的影响。
对81例无亲缘关系的土耳其肺癌患者进行了HLA I类（A、B、C）抗原和II类（DR、DQ）等位基因的分布研究。将患者的HLA状态与由117名种族匹配的健康供体组成的对照组进行比较。通过Terasaki微量淋巴细胞毒性试验研究HLA I类抗原，通过序列特异性引物聚合酶链反应（PCR-SSP）低分辨率方法研究HLA II类等位基因。
与健康对照患者相比，肺癌组中只有HLA-B51和-DRB1x15的频率较低。在单因素分析中，年龄（P=0.03）、卡诺夫斯基功能状态（P=0.0001）、分期（P=0.01）、HLA-A24(9)（P=0.008）、HLA B53（P=0.0006）、HLA B63(15)（P=0.01）、HLA B64(14)（P=0.01）、HLA B65(14)（P=0.01）和HLA CW5（P=0.01）是显著的预后因素。在多因素分析中，卡诺夫斯基功能状态（P=0.001）、分期（P=0.02）、HLA B53（P=0.03）和HLA B64(14)（P=0.03）是独立的预后变量。
本研究证明肺癌患者和健康对照者之间存在不同的HLA类型。我们的结果表明，HLA抗原可能影响肺癌的预后。有必要进一步研究以阐明HLA系统在肺癌发病机制和预后中的任何可能作用。
